The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Trump's order seeks to ease regulations to compel more U.S. drug manufacturing. He also plans to assess tariffs on drug ...

Molecular-guided decision-making improves disease control and remission in the treatment of IBD with anti-TNF therapy, ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's tirzepatide showed significantly greater weight loss than Novo Nordisk's semaglutide in a 72-week clinical trial ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Novo Nordisk shares dropped 5% in early trading on Monday after Eli Lilly released new trial data showing its weight loss ...

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...